Fertility chain Indira IVF is reportedly in advanced talks to acquire a majority stake in Kerala-based Sabine Hospital and Research Centre for up to Rs 1,300 crore. This potential acquisition is part of the firm's expansion strategy ahead of its planned IPO, providing an exit for investor CX Partners while intensifying competition in the South Indian market.
Indira IVF, the country's largest fertility services provider, is in discussions to acquire a 70% to 75% stake in the Kerala-based Sabine Hospital and Research Centre. The potential deal is valued between Rs 1,200 crore and Rs 1,300 crore. This move serves as a planned exit for CX Partners, which invested in the hospital chain only last year. The transaction is being facilitated by O3 Capital.
Sabine Hospital, founded in 2010 by Dr. Sabine Sivadasan, operates two facilities in Kerala with 300 beds, including specialized neonatal care capacity. The chain handles over 6,000 IVF cycles annually. For Indira IVF, this acquisition would represent a strategic entry point into Kerala, a region with changing demographic trends and increasing demand for specialized fertility care.
The company is aggressively scaling its operations, backed by global investor EQT Partners, as it prepares for a public listing that reportedly aims to raise Rs 3,500 crore. Indira IVF has recently executed a series of acquisitions in Kolkata, Puducherry, and Gujarat to build a national presence. The current consolidation in the fertility sector is driven by the need to scale quickly to capture a wider patient base.
The fertility sector in India is witnessing heightened competitive activity. Nova IVF Fertility, a major competitor, recently entered the Kerala market by acquiring Craft Fertility. This highlights a broader trend where larger chains are acquiring established regional players to bypass the time-consuming process of building new medical infrastructure from scratch.
Investors should consider the complexities associated with such large-scale healthcare acquisitions. While consolidation can offer revenue growth, integrating large hospital chains with high bed counts presents operational challenges compared to smaller clinic networks. Additionally, the fertility sector in India operates under the Assisted Reproductive Technology (Regulation) Act, which mandates strict compliance with medical standards, data privacy, and clinical practices. Any changes in regulatory oversight or issues with integrating the new assets could influence the project's success. The next steps for the company will involve finalizing the valuation, completing due diligence, and navigating regulatory approvals before the deal is officially confirmed.